Home

Zynerba Pharmaceuticals Nasdaq

Zynerba Pharmaceuticals, Inc. Common Stock (ZYNE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets Zynerba Pharmaceuticals, Inc. Common Stock (ZYNE) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets As at March 2021, Zynerba Pharmaceuticals had cash of US$93m and no debt. In the last year, its cash burn was US$42m. Therefore, from March 2021 it had 2.2 years of cash runway. Notably, analysts. Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. The firm offers Zygel product, which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is. Z ynerba Pharmaceuticals (ZYNE) closed at $4.15 in the latest trading session, marking a +1.47% move from the prior day. This change lagged the S&P 500's 1.95% gain on the day. Elsewhere, the Dow..

Zynerba Pharmaceuticals has such a small amount of debt that we'll set it aside, and focus on the US$59m in cash it held at December 2020. Importantly, its cash burn was US$42m over the trailing. Zynerba Pharmaceuticals Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, sowie aktuelle Nachrichten und Meinungen Die Zynerba Pharmaceuticals Inc Aktie wird unter der ISIN US98986X1090 an den Börsen Frankfurt, München, Stuttgart, Berlin, NASDAQ, SETSqx, Moskau, Bats, BX World, NDB, Gettex, Tradegate, Lang.

Here's Why Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) is an Attractive Investment Right Now. The trading price of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) closed higher on Friday, Apr 23, closing at $4.08, 3.19% higher than its previous close DEVON, Pa., May 27, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and..

Analysts Offer Insights on Healthcare Companies: Zynerba

ZYNERBA PHARMACEUTICALS INC. (A14XCV | US98986X1090) mit aktuellem Aktienkurs, Charts, News und Analysen Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) trade information After registering a -7.48% downside in the last session, Zynerba Pharmaceuticals, Inc. (ZYNE) has traded green over the past five days. The stock hit a weekly high of $4.52- this Wednesday, Apr 21, jumping 9.73% in its intraday price action Zynerba is a small ' Tier 4 ' developmental concern based just outside of Philadelphia. The company's current developmental efforts are centered around Zygel, the first and only.. Zynerba Pharmaceuticals (NASDAQ: ZYNE) hat zuletzt am Mittwoch seine Quartalsergebnisse veröffentlicht. Kann 12 th. Das Unternehmen berichtete ($ 0. 00) EPS für das Quartal und übertrifft damit die Konsensschätzung von ($ 0. 19) um $ 0. . Eine Reihe von Aktienanalysten haben Berichte über das Unternehmen veröffentlicht. Cantor Fitzgerald erhöhte sein Kursziel für Zynerba. April 22, 2021. Finance. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) price on Wednesday, Apr 21, rose 15.14% above its previous day's close as an upside momentum from buyers pushed the stock's value to $4.41

Here's Why We're Not Too Worried About Zynerba - Nasda

(NASDAQ: ZYNE) Zynerba Pharmaceuticals's market cap is $209.15M, as of Jun 3, 2021. Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares. Zynerba Pharmaceuticals 's market cap is calculated by multiplying ZYNE 's current stock price of $5.07 by ZYNE 's total outstanding shares of 41,251,537 In the last trading session, 1,064,951 Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) shares changed hands as the company's beta touched 2.51. With the company's per share price at $3.88 changed hands at -$0.09 or -0.02% during last session, the market valuation stood at $160.06 Million

ZYNE Stock Price and Chart — NASDAQ:ZYNE — TradingVie

Data on historical trading for Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) indicates that the trading volumes over the past 10 days have averaged 1.49 Million and over the past 3 months, they've averaged 5.58 Million. According to company's latest data on outstanding shares, there are 41.25 Million shares outstanding In the last trading session, 1,627,301 shares of the Zynerba Pharmaceuticals, Inc.(NASDAQ:ZYNE) were traded, and its beta was 2.54. Most recently the company's share price was $4.5, and it changed around $0.29 or 0.07% from the last close, which brings the market valuation of the company to $ ZYNERBA PHARMACEUTICALS, INC. ist ein Spezialpharmaunternehmen. Das Unternehmen beschäftigt sich mit der Entwicklung und Kommerzialisierung von transdermalen synthetischen Cannabinoidbehandlungen.

© 2021 Zynerba Pharmaceuticals, Inc. All rights reserved. 80 W. Lancaster Avenue, Suite 300 Devon, PA 19333 484.581.750 Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) has a beta value of 2.49 and has seen 1.13 million shares traded in the last trading session. The company, currently valued at $215.30M, closed the last trade at $5.43 per share which meant it lost -$0.23 on the day or -4.06% during that session. The ZYNE Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) went up by 4.84% from its latest closing price compared to the recent 1-year high of $9.00. The company's stock price has collected -0.46% of loss in the last five trading sessions. Press Release reported on 04/06/21 that Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conferenc Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. The ASCP annual meeting is being held virtually June 1-4, 2021. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) traded at $4.68 at close of the session on Monday, May 24, made a downturn move of -3.31% on its previous day's price. Get the hottest stocks to trade every day before the market opens 100% free. Click here now. Looking at the stock we see that it Zynerba Pharmaceuticals (NASDAQ:ZYNE) Intraday Stock Chart Sunday 13 June 2021 Your Recent History LSE. GKP Gulf Keyst.. LSE. QPP Quindell FTSE. UKX FTSE 100 LSE. IOF Iofina FX. GBPUSD UK Sterlin.. Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously. Register now to create your own custom streaming stock watchlist. NYSE, AMEX, and ASX quotes.

Zynerba Pharmaceuticals (ZYNE) Gains But Lags - Nasda

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) disclosed Wednesday its first-quarter net loss of $8.0 million or a loss of 20 cents per share, compared to $12.34 million in the same period of 2020 or. Zynerba Pharmaceuticals Inc. [NASDAQ: ZYNE] gained 49.26% on the last trading session, reaching $7.03 price per share at the time. The company report on March 10, 2021 that Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights.. Get the hottest stocks to trade every day before the market opens 100% free

Stock analysis for Zynerba Pharmaceuticals Inc (ZYNE:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) traded at $5.64 at close of the session on Friday, June 11, made an upward move of 4.06% on its previous day's price. Get the hottest stocks to trade every day before the market opens 100% free. Click here now. Looking at the stock we see that its Zynerba Pharmaceuticals (NASDAQ: ZYNE) hat zuletzt am Mittwoch, den März, seine Quartalsergebnisse veröffentlicht 400 th. Das Unternehmen berichtete ($ 0. 16) Gewinn pro Aktie für das Quartal, ohne die Konsensschätzung von Zacks von (0 USD). ) von ($ 0. ). Aktienanalysten sagen voraus, dass Zynerba Pharmaceuticals, Inc. als Gruppe einen Wert von -2 erzielen wird. Ergebnis je Aktie für das. Zynerba Pharmaceuticals (NASDAQ: ZYNE) is on an absolute roll right now.Indeed, over the past five trading days, ZYNE stock has nearly doubled. Today, shares of this cannabis-related specialty. Zynerba Pharmaceuticals (NASDAQ: ZYNE): An Overlooked Gem May 15, 2020 by Chris Stang 4 Comments When I say marijuana in the context of the stock market, you probably immediately think pot stocks and the likes of Cronos Group, Canopy Growth Corporation, and Aurora Cannabis

Prior to joining Zynerba, she served as head of Medical Affairs for NuPathe (NASDAQ: PATH) through approval and pre-launch of its lead product, Zecuity, the first transdermal patch for migraine, prior to the company being acquired by Teva Pharmaceuticals in 2014. Previously, Dr. Gutterman served in a variety of executive roles at GlaxoSmithKline for more than 20 years. There she was. Armando Anido has been the CEO of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) since 2014, and this article will examine the executive's compensation with respect to the overall performance of the. (NASDAQ: ZYNE) Zynerba Pharmaceuticals's 52-week high was $9.00, and its 52-week low was $3.12. It is currently -43.67% from its 52-week high and 62.5% from its 52-week low. How much is Zynerba Pharmaceuticals stock worth today? (NASDAQ: ZYNE) Zynerba Pharmaceuticals currently has 41,251,537 outstanding shares. With Zynerba Pharmaceuticals stock trading at $5.07 per share, the total value of.

Zynerba Pharmaceuticals (ZYNE) Nasdaq Global Market. ZYNE. $5.16 -$0.02 -0.4% Price as of June 4, 2021, 4:00 p.m. ET View Interactive ZYNE Charts. Zynerba Pharmaceuticals, Inc.. Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a pharmaceutical company focused on developing and marketing synthetic cannabinoid therapeutics for transdermal delivery. These therapetics seek to meet the unmet needs of patients with epilepsy, osteoarthritis, fibromyalgia, peripheral neuropathic pain, and Fragile X syndrome. Zynerba's product pipeline includes two drugs being developed: ZYN001 and.

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good

  1. Zynerba Pharmaceuticals Inc. Die Zynerba Pharmaceuticals Inc Aktie wird unter der ISIN US98986X1090 an den Börsen Frankfurt, München, Stuttgart, Berlin, NASDAQ, SETSqx, Moskau, Bats, BX World.
  2. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced its quarterly earnings results on Wednesday, May, 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the ' consensus estimate of ($0.25) by $0.05. View Zynerba Pharmaceuticals' earnings history. How has Zynerba Pharmaceuticals' stock been impacted by Coronavirus? Zynerba Pharmaceuticals.
  3. ZYNERBA PHARMACEUTICALS : Says Zygel Improved Sleep for Children With Developme.. 11.06. Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Chi.. 09.06. ZYNERBA PHARMACEUTICALS : Announces Adjournment of Annual Meeting (Form 8-K) 09.06. ZYNERBA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits.. 09.06
  4. Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE)'s beta value is holding at 2.53, while the average true range (ATR) indicator is currently reading 0.36. Considering analysts have assigned the stock a price target range of $4.5-$9 as the low and high respectively, we find the trailing 12-month average consensus price target to be $7.63. Based on this estimate, we see that current price is roughly.
  5. Headline. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Short Interest Down 35.5% in May. americanbankingnews.com - June 14 at 6:18 AM. Zynerba Pharmaceuticals showcases Zygel study poster at annual SLEEP meeting. proactiveinvestors.com - June 11 at 7:46 PM. Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies
  6. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) shares, rose in value on Wednesday, Apr 28, with the stock price up by 5.68% to the previous day's close as strong demand from buyers drove the stock to $4.65. Get the hottest stocks to trade every day before the market opens 100% free. Click here now
  7. Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) trade information. In the face of being in the red during last session for losing -8.03%, in the last five days ZYNE remained trading in the green while hitting it week-highest on Friday, Apr 30 when the stock touched $4.59-1 price level, adding 12.64% to its value on the day

04.06.2021 - DEVON, Pa., June 04, 2021 (GLOBE NEWSWIRE) - Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for. Zynerba to host conference call and webcast today, August 14 at 8:30 am ET Devon, PA, Aug. 14, 2017 - Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid treatments, today reported top line results from its Phase 2 STOP (Synthetic Transdermal. What We Learned About Zynerba Pharmaceuticals' (NASDAQ:ZYNE) CEO Compensation. Valuation. Is Zynerba Pharmaceuticals undervalued compared to its fair value and its price relative to the market? 49.2%. Undervalued compared to fair value. Share Price vs. Fair Value. Below Fair Value: ZYNE ($5.63) is trading below our estimate of fair value ($11.09) Significantly Below Fair Value: ZYNE is trading. Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X Syndrome - Confirmatory pivotal trial expected to be initiated in the third quarter of 2021 - - Zynerba to hold conference call today, May 5, 2021 at 5:30 pm ET - Devon, PA, May 5, 2021 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced. Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operating Highlights - RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, expected to be initiated in the third quarter of 2021 - - Cash runway well into first half 2024; $93.1 million at March 31, 2021 - Devon, PA, May 12, 2021 - Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in.

Zynerba Pharmaceuticals Aktie (A14XCV, US98986X1090, 6ZY

  1. Ein 02 - - 2020 (Dienstag) Aktien von Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) stieß auf a Differenz von -0. 52% Danach wurde die Tagessitzung bei 3 US-Dollar geschlossen. 20. Das Volumen addierte 1, 301, 201 Aktien, die mit dem durchschnittlichen Volumen von 1 verglichen werden. 61 M Aktien. Zynerba Pharmaceuticals, Inc. , ein in den USA ansässiges Unternehmen, gehört zu Drug.
  2. GW Pharmaceuticals Plc (NASDAQ:GWPH) and Zynerba Pharmaceuticals (NASDAQ:ZYNE) are both developing cannabidiol-based pharmaceutical products for the treatment of orphan indication epileptic.
  3. Zynerba Pharmaceuticals (NASDAQ:ZYNE): Q1 GAAP EPS of -$0.20 beats by $0.05.; Cash and cash equivalents of $93.1M as of March 31, 2021. Management believes that the Company's cash and cash.
  4. Zynerba Pharmaceuticals (NASDAQ:ZYNE) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. According to Zacks, Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics.
  5. Zynerba Pharmaceuticals (NASDAQ:ZYNE) shares closed up 7.76% at $4.86 Zelira Therapeutics (OTC: ZLDAF ) shares closed up 7.76% at $0.04 Golden Leaf Holdings (OTC: GLDFF ) shares closed up 7.74% at.
  6. Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) - Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative.

Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting. DEVON, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative. ZYNERBA PHARMACEUTICALS, INC. : Börsenempfehlungen, Brokereanalysen- und empfehlungen für der Aktie ZYNERBA PHARMACEUTICALS, INC. | A14XCV | US98986X1090 | Nasdaq Auf 08 - 13 - 2020 (Donnerstag) Aktien von . Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) hat einen Unterschied von -0 festgestellt. % danach wurde die Tagessitzung bei $ 3 geschlossen. 93. Das hinzugefügte Volumen 393, 300 Aktien, die verglichen werden mit einem durchschnittlichen Volumen von 1. 70 M Aktien. Zynerba Pharmaceuticals, Inc. , ein in den USA ansässiges Unternehmen, gehört. Zynerba Pharmaceuticals (NASDAQ: ZYNE) reported Q1 2021 earnings per share (EPS) of -$0.20, up 62.26% year over year. Total Zynerba Pharmaceuticals earnings for the quarter were -$7.96 million. In the same quarter last year, Zynerba Pharmaceuticals's earnings per share (EPS) was -$0.53 Zynerba Pharmaceuticals (NASDAQ:ZYNE) Earnings Information. Zynerba Pharmaceuticals last released its quarterly earnings results on May 12th, 2021. The reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.05. Zynerba Pharmaceuticals has generated ($1.90) earnings per share over the last year. Zynerba Pharmaceuticals has not formally.

DEVON, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2021, and provided an overview of recent operational highlights and a pipeline update Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) went up by 7.06% from its latest closing price compared to the recent 1-year high of $9.00. The company's stock price has collected -3.89% of loss in the last five trading sessions. Press Release reported on 03/28/21 that Zynerba (ZYNE) Alert: Shareholde Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) went down by -0.89% from its latest closing price compared to the recent 1-year high of $9.00. The company's stock price has collected 5.28% of gains in the last five trading sessions. Press Release reported 9 hours ago that Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting. Get the hottest stocks to trade every day before the market. Zynerba Pharmaceuticals, Inc NASDAQ. Follow Following Unfollow Trade now . Upcoming Earnings. EPS. Market Cap. Div Yield. P/E. Upcoming Earnings. EPS. Market Cap. Div Yield. P/E. Trade now Follow Following Unfollow. Overview Ideas Technicals . Financials . Financial statements Zynerba Pharmaceuticals, Inc key financial stats and ratios If you want to check out ZYNE market capitalization, P/E. NASDAQ ZYNE opened at $5.52 on Thursday. Zynerba Pharmaceuticals has a 12 month low of $2.55 and a 12 month high of $9.00. The company has a 50-day moving average of $4.10 and a 200-day moving average of $3.86. The company has a market cap of $162.50 million, a P/E ratio of -3.03 and a beta of 2.83. Zynerba Pharmaceuticals Company Profil

Zynerba Pharmaceuticals EPS beats by $0.05 Zynerba receives FDA guidance for Phase 3 trial design for Zygel in rare genetic disorder Zynerba Pharmaceuticals EPS in-lin Zynerba Pharmaceuticals, Inc NASDAQ. Follow Following Unfollow Trade now . Upcoming Earnings. EPS. Market Cap. Div Yield. P/E. Upcoming Earnings. EPS. Market Cap. Div Yield. P/E. Trade now Follow Following Unfollow. Overview Ideas Technicals . Financials . Financial statements Zynerba Pharmaceuticals, Inc financial statements, including revenue, expenses, profit, and loss The annual and. DEVON, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near.

ZYNERBA PHARMACEUTICALS AKTIE Aktienkurs Kurs

Here's Why Zynerba Pharmaceuticals, Inc

The clinical stage specialty pharmaceutical company that focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) seems to be getting ready for a price surge according to its latest charts. Bullish Move - Chart Indications #1 Channel Breakout: As you can see from the daily. Nasdaq; Zynerba Pharmaceuticals, Inc. News. Summary ZYNE US98986X1090. ZYNERBA PHARMACEUTICALS, INC. (ZYNE) Add to my list. Report. Real-time Estimate Cboe BZX - 06/11 01:30:47 pm: 5.625: USD +3.78%: 12:30p: Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder. Auf - - 2020 (Freitag) Aktien von . Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) hat einen Unterschied von -1 festgestellt. % danach wurde die Tagessitzung bei $ 4 geschlossen. 08. Das hinzugefügte Volumen 542, 600 Aktien, verglichen mit dem durchschnittlichen Volumen von 1. 77 M Aktien. Zynerba Pharmaceuticals, Inc. , ein in den USA ansässiges Unternehmen, gehört zu Drug Manufacturers. Zynerba Pharmaceuticals Aktie: Hier finden Sie den Zynerba Pharmaceuticals Aktienkurs aktuell und ausserdem weitere Informationen wie den Zynerba Pharmaceuticals Char DEVON, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near.

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE) and autism spectrum disorder. News zur ZYNERBA PHARMACEUTICALS AKTIE und aktueller Realtime-Aktienkurs Zynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel in Children and Adolescents.

ZYNE Stock - Zynerba Pharmaceuticals, Inc

ZYNERBA PHARMACEUTICALS INC

Ausführliches Aktienporträt der Zynerba Pharmaceuticals - WKN A14XCV, ISIN US98986X1090 - bei finanztreff.de topaktuell Zynerba Pharmaceuticals Inc. [NASDAQ: ZYNE] gained 7.58% on the last trading session, reaching $5.68 price per share at the time. The company report on May 27, 2021 that Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.. Get the hottest stocks to trade every day before the market opens 100% free

Zynerba Pharmaceuticals has such a small amount of debt that we'll set it aside, and focus on the US$59m in cash it held at December 2020. Importantly, its cash burn was US$42m over the trailing twelve months. Therefore, from December 2020 it had roughly 17 months of cash runway. Importantly, analysts think that Zynerba Pharmaceuticals will reach cashflow breakeven in 5 years. Essentially. Dienstag, 30.06.2020 - 15:00 Uhr - Chartanalyse HotStocks USA: -39% bei ZYNERBA PHARMA Anbei erhalten Sie eine Übersicht über die Werte, die vorbörslich an der Nasdaq am meisten. Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) were crashing 18.3% lower as of 10:48 a.m. EDT on Wednesday after falling as much as 26.5% earlier in the morning. The big plunge came after Zynerba. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) -3.31% Decline Turns Away Investor Interest In Company's Stock stocksregister 5/25/2021 Zynerba Pharmaceuticals Inc (ZYNE

Armando Anido has been the CEO of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) since 2014, and this article will examine the executive's compensation with respect to the overall performance of the company.This analysis will also assess whether Zynerba Pharmaceuticals pays its CEO appropriately, considering recent earnings growth and total shareholder returns View Zynerba Pharmaceuticals, Inc. ZYNE investment & stock information. Get the latest Zynerba Pharmaceuticals, Inc. ZYNE detailed stock quotes, stock data, Real-Time ECN, charts, stats and more Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) investors should pay attention to an increase in activity from the world's largest hedge funds of late. ZYNE was in 7 hedge funds' portfolios at the end.

Zeroing In On Zynerba Pharmaceuticals (NASDAQ:ZYNE

ZYNE Zynerba Pharmaceuticals — Stock Price and Discussion | Stocktwits. DOW 0.03%. S&P 500 0.48%. NASDAQ 1.10%. Trending now. Zynerba Pharmaceuticals 5.64 0.22 (4.06%) Zynerba Pharmaceuticals NASDAQ Updated Jun 11, 2021 4:59 PM Zynerba Pharmaceuticals | 3,107 followers on LinkedIn. Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high. Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its earnings results on Monday, November 9th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of. DEVON, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will present a company overview during the 20 th Annual Needham Virtual Healthcare Conference.

Is GW Pharma (NASDAQ: GWPH) Now The Future Of Cannabis

Zynerba Pharmaceuticals Stock Price Today (NASDAQ: ZYNE

A. The stock price for Zynerba Pharmaceuticals ( NASDAQ: ZYNE) is $ 5.07 last updated Tue Jun 01 2021 20:00:02 GMT+0000 (Coordinated Universal Time). Q Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares ended Monday's session nearly 15% higher after Canaccord Genuity said the stock's mid-September sell-off was unjustified.. The Analyst. Sumant. DEVON, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today provided an update on its meeting with the U.S. Food and Drug Administration (FDA) regarding its Fragile X syndrome (FXS) program. The Company plans to conduct a.

Zynerba reports 'exciting step forward' with experimental

Let's Discuss The Zynerba Pharmaceuticals, Inc

Идеи и прогнозы по Zynerba Pharmaceuticals, Inc от авторов TradingView — они делятся результатами теханализа и публикуют обзоры рынка акций, Форекс, криптовалют и т. д Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced the acceptance and presentation details of two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The SOBP annual meeting is being held virtually from April 29 through May 1. ZYNERBA PHARMACEUTICALS INC: NASDAQ: ZYNE: currency: USD Stock Common: ZYNERBA PHARMACEUTICALS INC: ZYNE: Latest USPTO Trademark Filings . Mark Image. Registration | Serial. Trademark. Application Date QIETIFY 88519283. QIETIFY. 2019-07-17 ZYGEL 88291596. ZYGEL. 2019-02-06 Z 4847465 86398253. Z. 2014-09-18 ZYNERBA 4847362 86382658. ZYNERBA . 2014-09-02 ALLTRANZ 4564661 85599967. Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) went down by -0.24% from its latest closing price compared to the recent 1-year high of $9.00. The company's stock price has collected -3.03% of loss in the last five trading sessions. Press Release reported on 05/05/21 that Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel(TM) in Fragile X Syndrom DEVON, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near.

Zynerba: Why I'm Not Buying The High - ZynerbaNemus (OTC:NMUS) Talks 'Waves Of Dominance' In TheZynerba Pharmaceuticals (ZYNE) Stock Message BoardDefensive Strategies For Sage Therapeutics In The

Shares of Zynerba Pharmaceuticals ( NASDAQ:ZYNE) were shooting 18.9% higher as of 10:57 a.m. EDT on Tuesday. The big jump came after the biotech announced that it received a new patent for. Zynerba Pharmaceuticals, Inc NASDAQ. Follow Following Unfollow Trade now . Upcoming Earnings. EPS. Market Cap. Div Yield. P/E. Upcoming Earnings. EPS. Market Cap. Div Yield. P/E. Trade now Follow Following Unfollow. Overview Ideas Technicals . Financials . Financial statements The current financial position of Zynerba Pharmaceuticals, Inc Total assets of ZYNE for Q1 21 is 108.81M, 46.93% more. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) unveiled a poster highlighting sleep data from a study of its Zygel transdermal cannabinoid therapy at the Associated Professional Sleep Societies, SLEEP 2021 Annual meeting.. This year's SLEEP meeting is being held virtually and runs from June 10 through June 13. Zynerba's study was conducted on children and adolescents with both developmental and. Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common. Die Zynerba Pharmaceuticals-Aktien notieren unter der WKN bzw. der ISIN US98986X1090 . mit einem sehr hohe Streubesitz von 96.7%. Die Zynerba Pharmaceuticals Inc Aktie wird unter der ISIN US98986X1090 an den Börsen Frankfurt, München, Stuttgart, Berlin, NASDAQ, SETSqx, Bats, BX World, NDB, Tradegate, Lang & Schwarz und Baader Bank gehandelt Zynerba Pharmaceuticals 80 W. Lancaster Avenue Suite 300 Devon, PA 19333 484.581.7505. What is Zynerba's ticker symbol? Zynerba trades on NASDAQ under the ticker ZYNE. Who is Zynerba's transfer agent? How do I transfer stock, change the address on my shareholder account, or replace a lost stock certificate? For any questions regarding your holdings, please contact our transfer agent.

  • Seedlip Grove 42 cocktail.
  • Moore's Law end.
  • RimWorld Zzzt.
  • Catalina Island Punta Cana.
  • Economic Value Added Advantages and disadvantages.
  • Caseking Gehalt.
  • Will Bitcoin make me rich Reddit.
  • Tomtkö Malmö logga in.
  • OTC Aktien Screener.
  • MetaTrader 5 Alarm einstellen.
  • Golf 8 GTE Software.
  • 5G Glasfaser Hersteller.
  • Yearn treasury.
  • Riot Blockchain Prognose.
  • Exibel bxlp 45 review.
  • FT Tesla bitcoin.
  • Digitaler Kassenbon REWE.
  • Fondspar.
  • Unerlaubte Werbung melden.
  • Stratis RAID.
  • IOTA CEO.
  • Blockfi andrei jikh.
  • Vespa 50cc prijs.
  • Trawler Deutsch.
  • How to create p12 certificate for ios distribution.
  • Gaming PC B Ware.
  • Orient meaning in Marathi.
  • 5G Glasfaser Hersteller.
  • NairaEx Sign In.
  • Visage нет фотоаппарата.
  • McAfee Endpoint Security preis.
  • Anycoin Direct Deutschland gesperrt.
  • HSBC Private Bank Singapore.
  • Ivoris Kamera.
  • Reise mit Bitcoin bezahlen.
  • Finanzielle Unabhängigkeit wie viel Geld.
  • Batteri till elmotorcykel barn.
  • Komodo dragon poison.
  • VPRO documentary.
  • Aktien App.
  • BOLT Global.